Crossmark

Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

Crossref DOI link: https://doi.org/10.1038/srep11827

Published Online: 2015-07-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Basarab, Gregory S.

Kern, Gunther H.

McNulty, John

Mueller, John P.

Lawrence, Kenneth

Vishwanathan, Karthick

Alm, Richard A.

Barvian, Kevin

Doig, Peter

Galullo, Vincent

Gardner, Humphrey

Gowravaram, Madhusudhan

Huband, Michael

Kimzey, Amy

Morningstar, Marshall

Kutschke, Amy

Lahiri, Sushmita D.

Perros, Manos

Singh, Renu

Schuck, Virna J. A.

Tommasi, Ruben

Walkup, Grant

Newman, Joseph V.
License Information

Text and Data Mining valid from 2015-07-14

Version of Record valid from 2015-07-14
More Information

Article History

Received: 23 March 2015

Accepted: 4 June 2015

First Online: 14 July 2015

Change Date: 18 September 2015

Change Type: Update

Change Details: A correction has been published and is appended to both the HTML and PDF versions of this paper. The error has not been fixed in the paper.

Competing interests

: The authors are or have been employed by AstraZeneca and declare no competing financial interests otherwise.

Updates are available Correction dated 2015-09-18

Click to view Correction: https://doi.org/10.1038/srep14157